ArticleAntibiotics (Basel, Switzerland)2020
Pan-Drug Resistant
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Stigmurin derivatives as potent-biofilm eradicating agents against the major human opportunistic pathogenFrontiers in microbiology · 2026Article
- Therapeutic Bioactivity Exerted by theMolecules (Basel, Switzerland) · 2025Article
- A leucine responsive small RNA AbcR200 regulates expression of the lactate utilization (lut) operon in Acinetobacter baumannii DS002.The Journal of biological chemistry · 2025Article
- A review on the screening methods for the discovery of natural antimicrobial peptides.Journal of pharmaceutical analysis · 2025Review
- Fluopsin C Promotes Biofilm Removal of XDRAntibiotics (Basel, Switzerland) · 2024Article
- Cell-Free Systems: Ideal Platforms for Accelerating the Discovery and Production of Peptide-Based Antibiotics.International journal of molecular sciences · 2024Review
- Enhancing effect of natural adjuvant, panduratin A, on antibacterial activity of colistin against multidrug-resistant Acinetobacter baumannii.Scientific reports · 2024Article
- The Synthetic Antimicrobial Peptide Derived From Melittin Displays Low Toxicity and Anti-infectious Properties.Probiotics and antimicrobial proteins · 2024Article
- Discovery of Melittin as Triple-Action Agent: Broad-Spectrum Antibacterial, Anti-Biofilm, and Potential Anti-Quorum Sensing Activities.Molecules (Basel, Switzerland) · 2024Article
- Article
- An Update on the Therapeutic Potential of Antimicrobial Peptides againstPharmaceuticals (Basel, Switzerland) · 2023Review
- Antimicrobial Peptide Cec4 Eradicates Multidrug-ResistantDrug design, development and therapy · 2023Article
- Bugs on Drugs: AMicroorganisms · 2022Article
- Detrimental Effect of Ozone on Pathogenic Bacteria.Microorganisms · 2021Article
- Colistin and Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Promising Antimicrobial Properties of Bioactive Compounds from Different Honeybee Products.Molecules (Basel, Switzerland) · 2021Review
- Antimicrobial Properties ofToxins · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.